Present Drug Therapy of Demyelinating Disorders

Title:Present Drug Therapy of Demyelinating Disorders

Volume: 13 Issue: 1

Author(s): Yuval Karmon and Natan Gadoth*

Affiliation:

• The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,Israel

Keywords: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Disease Modifying Treatment (DMT), interferon beta, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, corticosteroids, IV immunoglobulins, rituximab, alemtuzumab, ocrelizumab, daclizumab, mycophenolate mofetil.

Abstract: Background: Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system, destroying the myelin and the axon in variable degrees and causing significant disability in many patients. Neuro-Myelitis Optica Spectrum Disorder (NMOSD) is a rare disorder that was considered a subtype of MS but is now recognized as a distinct demyelinating disorder that affects mainly the spine and optic nerves.

Objective: The present paper is a review of the recent knowledge regarding present and new drugs that have been recently added to the therapeutic arsenal for MS as well as those which seem to be beneficial for patients with NMOSD.

Methods: A step-by-step description of the evolving drug arsenal is presented for both MS and Neuro-Myelitis Optica Spectrum Disorder (NMOSD).

Results: Modern drug therapy for MS started with the introduction of ACTH (Adrenocorticotropic hormone) and somewhat later was followed by high dose corticosteroids for treatment of the neurological deficits during an acute relapse. This mode of treatment, which became popular during the years 1970-1980 failed to reduce the number of relapses or to affect the outcome of the disease. Only during the last two decades, the field of MS drug therapy underwent a remarkable change from simple amelioration of symptoms of an acute attack to the development of numerous Disease Modifying Treatments (DMTs). The formulation of DMTs evolved from the older inconvenient subcutaneous or intramuscular route of administration to oral preparations or periodic intravenous infusions of biological drugs. A new treatment was approved in 2017 for reducing disease progression rate for the first time in primary progressive MS.

Besides MS, progress was made in delineating the pathophysiology of NMOSD, a devastating demyelinating disorder that is still frequently confused with MS.

Although beneficial, the new treatment modalities carry with them adverse effects that may be serious and even life threatening. With the increase in the usage of those drugs, the spectrum of the reported adverse effects is expanding and calls for additional research in regard to the safest way of their utilization.

Conclusion: Targeting the immune system in general in RRMS and NMOSD and even PPMS has proven successful, with efficacy varying based on the specific treatment. There are still unmet needs for medications that will address safety and efficacy altogether and prevent disability even more.

Areas Covered: The mode of action and main characteristics and side effects of current DMTs for both MS and NMOSD and their place in the therapeutic algorithm of both diseases based on updated evidence from clinical trials.

Cite this article as:

Karmon Yuval and Gadoth Natan *, Present Drug Therapy of Demyelinating Disorders, Current Drug Therapy 2018; 13 (1) . https://dx.doi.org/10.2174/1574885512666170808094148